Oppenheimer raised the firm’s price target on Ligand (LGND) to $145 from $142 and keeps an Outperform rating on the shares following quarterly results. Ligand remains in early stages of executing their royalty strategy, and the firm expects continued execution across the portfolio, further supported by deal-making throughout 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND:
- Ligand Pharma’s Strong Q1 Performance and Strategic Moves Justify Buy Rating with $135 Price Target
- Ligand Pharmaceuticals Reports Strong Q1 2025 Revenue Growth
- Ligand Pharmaceuticals Reports Strong Q1 2025 Earnings
- Positive Outlook for Ligand Pharma: Strong Financial Performance and Strategic Positioning Justify Buy Rating
- Ligand sees FY25 adjusted EPS $6.00-$6.25, consensus $6.11